{"filings":[{"id":97109,"accession_number":"0001062993-26-002142","cik":1997296,"company_name":"Medicus Pharma Ltd.","ticker":"MDCX","form_type":"8-K","filed_at":"2026-04-24T23:59:59+00:00","items":["1.01","3.01","9.01"],"status":"ready","headline":"Medicus Pharma receives Nasdaq bid price deficiency notice; expands ATM to $50M","event_type":"regulatory","confidence":"high","bullets":["Nasdaq notified Medicus on April 21, 2026 that its stock bid price closed below $1.00 for 30 consecutive business days, non-compliant with Listing Rule 5550(a)(2).","Company has 180 days (until Oct 19, 2026) to regain compliance by closing at $1.00+ for 10 consecutive days.","Medicus increased ATM offering amount from ~$15.35M to $50M via Amendment No. 1; ~$11.5M already raised under the program."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":111620,"accession_number":"0001062993-26-001326","cik":1997296,"company_name":"Medicus Pharma Ltd.","ticker":"MDCX","form_type":"8-K","filed_at":"2026-03-06T23:59:59+00:00","items":["3.02","9.01"],"status":"ready","headline":"Medicus Pharma sells 4.47M shares for $3.85M under Yorkville SEPA through Mar 6, 2026","event_type":"other_material","confidence":"high","bullets":["Total of 4,471,038 common shares sold under SEPA from Dec 2025 to Mar 2026 for aggregate $3,846,910.","Largest single draw: 1,425,000 shares on Mar 6, 2026 for approx $640,110.","Proceeds used partly to prepay outstanding debenture with Yorkville (previously disclosed in Sep 2025 8-K).","Yorkville may resell shares under an effective registration statement; additional draws possible subject to SEPA conditions.","Sales rely on Section 4(a)(2) exemption; Yorkville represented itself as an accredited investor."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":128271,"accession_number":"0001062993-25-017492","cik":1997296,"company_name":"Medicus Pharma Ltd.","ticker":"MDCX","form_type":"8-K","filed_at":"2025-12-30T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"Medicus Pharma enters up to $15.35M ATM equity distribution agreement with Maxim and Yorkville","event_type":"other_material","confidence":"high","bullets":["ATM program for aggregate offering of up to $15,349,674 of common shares via Maxim Group and Yorkville Securities.","Commission of 3.0% of gross sales; agents also reimbursed for reasonable expenses.","Sales will be at-the-market on Nasdaq Capital Market; no obligation to sell any shares.","Shares to be issued under new S-3 registration statement filed December 29, 2025, pending SEC effectiveness."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":128270,"accession_number":"0001062993-25-017219","cik":1997296,"company_name":"Medicus Pharma Ltd.","ticker":"MDCX","form_type":"8-K","filed_at":"2025-12-08T23:59:59+00:00","items":["1.01","3.02","7.01","1.02","9.01"],"status":"ready","headline":"Medicus Pharma enters $5.1M warrant inducement; issues new warrants for 4M shares","event_type":"other_material","confidence":"high","bullets":["Gross proceeds ~$5.1M from exercise of 2,680,000 existing warrants at amended price of $1.92/share.","Issued new unregistered Series C/D warrants to purchase 4,020,000 common shares at $2.00, expiring June 5, 2031.","Company agreed to file resale registration statement for new warrant shares within 60 days of agreement.","Also reported SEPA sales of 680,893 common shares for ~$1.5M from Oct 28 to Dec 4, 2025.","Maxim Group LLC acted as exclusive financial advisor; 6.0% cash fee on gross proceeds."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":128269,"accession_number":"0001062993-25-017085","cik":1997296,"company_name":"Medicus Pharma Ltd.","ticker":"MDCX","form_type":"8-K","filed_at":"2025-12-01T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"Medicus Pharma appoints Carolyn Bonner as CFO; Jim Quinlan resigns for health reasons","event_type":"leadership","confidence":"high","bullets":["James Quinlan resigned as CFO effective Nov 28, 2025, after medical leave since Sep 12, 2025.","Carolyn Bonner, previously Acting CFO and President, appointed CFO effective Dec 1, 2025; will continue as President.","Bonner's amended employment agreement: annual base salary $395,000, bonus targets escalating from 60% to 100% over five years.","Bonner brings nearly 20 years healthcare/life sciences experience; previously CEO of PCL, Inc."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":128268,"accession_number":"0001062993-25-016864","cik":1997296,"company_name":"Medicus Pharma Ltd.","ticker":"MDCX","form_type":"8-K","filed_at":"2025-11-14T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Medicus Pharma Q3 net loss $16M, pipeline advances with SkinJect and Teverelix","event_type":"other_material","confidence":"high","bullets":["Net loss $16.0M in Q3 2025 vs $2.3M in Q3 2024; R&D $1.7M, G&A $5.0M.","Cash $8.7M at Sep 30, 2025, up from $5.3M; raised $10.4M from financings and warrant exercises.","Phase 2 SKNJCT-003 >75% enrolled; FDA Type C meeting supports 505(b)(2) pathway for D-MNA (BCC).","Completed Antev acquisition (Teverelix, GnRH antagonist) in August 2025; UK approvals for SKNJCT-003 expansion.","Strategic collaboration with Gorlin Syndrome Alliance for expanded access to SkinJect under FDA IND."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":128267,"accession_number":"0001062993-25-016179","cik":1997296,"company_name":"Medicus Pharma Ltd.","ticker":"MDCX","form_type":"8-K","filed_at":"2025-10-17T23:59:59+00:00","items":["3.02","9.01"],"status":"ready","headline":"Medicus Pharma sells 1.09M shares to Yorkville for $2.53M, repays debenture","event_type":"other_material","confidence":"high","bullets":["Sold 1,088,048 common shares to Yorkville between Sep 8 and Oct 16, 2025 at prices from $1.80 to $2.77.","Aggregate proceeds of $2,526,364 from the SEPA Advances.","Proceeds used to partially prepay a Yorkville debenture, as disclosed in Sep 18, 2025 8-K.","Yorkville may resell shares under an effective registration statement; further sales possible under SEPA subject to conditions."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":145063,"accession_number":"0001062993-25-015700","cik":1997296,"company_name":"Medicus Pharma Ltd.","ticker":"MDCX","form_type":"8-K","filed_at":"2025-09-18T23:59:59+00:00","items":["1.01","2.03","8.01","9.01"],"status":"ready","headline":"Medicus Pharma secures $8M non-dilutive debenture from Yorkville; net proceeds $5.7M","event_type":"debt","confidence":"high","bullets":["$8M principal, 8% interest, matures Sept 2026; monthly installments of $650k plus accrued interest.","Refinances ~$1.7M existing debt; net proceeds ~$5.7M after discount, fees, and debt repayment.","Proceeds to accelerate Teverelix (GnRH Antagonist) for AURr and high CV risk prostate cancer (~$6B market).","Optional redemption at any time at face value plus interest; Yorkville may force redemption from equity financings (excluding SEPA)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":145062,"accession_number":"0001062993-25-015601","cik":1997296,"company_name":"Medicus Pharma Ltd.","ticker":"MDCX","form_type":"8-K","filed_at":"2025-09-12T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Medicus Pharma CFO James Quinlan takes medical leave; President Carolyn Bonner named Acting CFO","event_type":"leadership","confidence":"high","bullets":["CFO James Quinlan began medical leave on September 12, 2025.","Carolyn Bonner, current President, appointed Acting CFO without additional compensation.","Bonner previously served as President & CEO of Parkway Clinical Laboratories (2019-2023).","No family relationships or reportable transactions between Bonner and company officers."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.45,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":145061,"accession_number":"0001062993-25-015149","cik":1997296,"company_name":"Medicus Pharma Ltd.","ticker":"MDCX","form_type":"8-K","filed_at":"2025-09-02T23:59:59+00:00","items":["2.01","3.02","5.02","8.01","9.01"],"status":"ready","headline":"Medicus Pharma completes Antev acquisition for ~$3M cash + 1.6M shares; up to $65M contingent","event_type":"m_and_a","confidence":"high","bullets":["Acquired 98.6% of Antev for ~$3.0M cash and 1,603,164 MDCX shares; up to $65M in contingent milestones tied to FDA Phase 2 and NDA approvals.","Antev develops Teverelix, a GnRH antagonist for acute urinary retention and high-CV-risk prostate cancer; targets ~$6B market.","Patrick J. Mahaffy, former Antev chairman and ex-CEO of Clovis Oncology, appointed to board; receives 25,000 stock options at $1.94 vesting quarterly over 12 months.","Consideration shares subject to staggered 210-day lock-up (15% released every 30 days from effective registration; final 10% at 210 days).","Sold 250,000 common shares to Yorkville via SEPA for ~$490,535 net proceeds; proceeds to prepay outstanding debentures."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":145060,"accession_number":"0001062993-25-014806","cik":1997296,"company_name":"Medicus Pharma Ltd.","ticker":"MDCX","form_type":"8-K","filed_at":"2025-08-22T23:59:59+00:00","items":["3.02","8.01","9.01"],"status":"ready","headline":"Medicus Pharma: FDA accepts Type C meeting; Phase 2 BCC study >75% randomized; Q2 net loss $6.2M","event_type":"other_material","confidence":"high","bullets":["FDA accepted Type C meeting request; written queries submitted, response expected before end of Q3 2025.","Phase 2 SKNJCT-003 randomized >75% of 90 participants; interim analysis showed >60% clinical clearance.","Cash $9.7M at Q2-end, up from $4.0M Q1; raised $11.5M net from financings and warrant exercises.","Q2 net loss $6.2M vs $3.6M YoY; operating expenses $6.0M vs $3.6M YoY.","CFO James Quinlan exercised 145,000 stock options for ~$156,250 in proceeds."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":145059,"accession_number":"0001062993-25-013468","cik":1997296,"company_name":"Medicus Pharma Ltd.","ticker":"MDCX","form_type":"8-K","filed_at":"2025-08-04T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Medicus Pharma signs non-binding MoU with HelixNano for thermostable mRNA vaccine development","event_type":"other_material","confidence":"high","bullets":["Non-binding MoU to combine Medicus' MNA delivery platform with HelixNano's mRNA platform for thermostable infectious disease vaccines.","Parties aim to form a joint venture for co-development and commercialization of thermostable mRNA-based vaccines.","Plan a Phase 1 bridging study comparing IM injection vs. intradermal MNA delivery of HelixNano's vaccine candidate HN-0001.","Preliminary activities include a Sponsored Research Agreement with University of Pittsburgh (Dr. Lou Falo), supply of HN-0001, and loading into Medicus' MNAs.","MoU is non-binding; no obligation to proceed with joint venture until definitive agreements are executed."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":145058,"accession_number":"0001062993-25-013266","cik":1997296,"company_name":"Medicus Pharma Ltd.","ticker":"MDCX","form_type":"8-K","filed_at":"2025-07-30T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Medicus Pharma hires Deloitte to find out-licensing partner for D-MNA (BCC)","event_type":"other_material","confidence":"high","bullets":["Deloitte appointed exclusive lead financial adviser for out-licensing D-MNA for basal cell carcinoma.","Company will pay Deloitte retainer plus contingent success fee if a transaction closes.","Engagement letter signed July 29, 2025; no partner identified yet."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":145057,"accession_number":"0001062993-25-013073","cik":1997296,"company_name":"Medicus Pharma Ltd.","ticker":"MDCX","form_type":"8-K","filed_at":"2025-07-23T23:59:59+00:00","items":["5.07","8.01","9.01"],"status":"ready","headline":"Medicus Pharma adds former Congresswoman McMorris Rodgers and Ajay Raju to board, all shareholder proposals passed","event_type":"leadership","confidence":"high","bullets":["All eight director nominees elected at July 22 meeting; new board members are Hon. Cathy McMorris Rodgers and Ajay Raju.","Shareholders approved all five proposals: auditor ratification, by-law quorum increase to 33⅓%, Nasdaq 20% Rule share issuance, and 75% board vote to remove Chairman.","Ajay Raju provided $8M seed investment in pre-IPO round; now serves as Chairman/CEO of Raju LLP and co-founder of Avstera Therapeutics.","Cathy McMorris Rodgers served as first female Chair of House Energy & Commerce Committee; retired from Congress in 2024.","Dr. Raza Bokhari continues as Executive Chairman and CEO; company focused on clinical-stage pharmaceutical R&D."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.55,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":145056,"accession_number":"0001062993-25-012767","cik":1997296,"company_name":"Medicus Pharma Ltd.","ticker":"MDCX","form_type":"8-K","filed_at":"2025-07-14T23:59:59+00:00","items":["1.01","3.02","9.01"],"status":"ready","headline":"Medicus Pharma enters warrant inducement for $3.75M gross; also sells $1.52M shares via SEPA","event_type":"other_material","confidence":"high","bullets":["Holder exercises 1.34M existing warrants at $2.80; receives 2.68M new warrants at $3.75 expiring in 5 years.","Gross proceeds from warrant exercise ~$3.75M; net used for clinical trials, working capital, and Antev acquisition costs.","Company sold 490,000 common shares to Yorkville via SEPA for net proceeds of ~$1.52M at ~$3.10/share.","Maxim Group LLC receives 6.0% cash fee on warrant exercise gross proceeds.","Company to file S-1 registration for resale of new warrant shares within 120 days."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":145055,"accession_number":"0001062993-25-012533","cik":1997296,"company_name":"Medicus Pharma Ltd.","ticker":"MDCX","form_type":"8-K/A","filed_at":"2025-07-03T23:59:59+00:00","items":["9.01"],"status":"ready","headline":"Medicus Pharma signs share exchange agreement to acquire Antev Limited","event_type":"m_and_a","confidence":"medium","bullets":["Agreement to acquire all Antev Shares; Antev becomes wholly-owned subsidiary of Medicus.","Consideration includes Purchaser Shares (Consideration Shares) and Contingent Consideration tied to milestones.","Antev's lead candidate Teverelix (for acute urinary retention) referenced in forward-looking statements.","Closing expected 3 Business Days after conditions satisfied; drag-along provisions apply for all shareholders."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":163445,"accession_number":"0001062993-25-012231","cik":1997296,"company_name":"Medicus Pharma Ltd.","ticker":"MDCX","form_type":"8-K","filed_at":"2025-06-30T23:59:59+00:00","items":["1.01","8.01","9.01"],"status":"ready","headline":"Medicus Pharma to acquire Antev Ltd. for ~17% equity stake + up to $65M contingent milestone payments","event_type":"m_and_a","confidence":"high","bullets":["Medicus will issue 2,666,600 common shares (~17% of outstanding) to acquire all Antev shares on a fully diluted basis.","Antev shareholders eligible for up to $65M in contingent consideration tied to FDA Phase 2 and NDA approvals for Teverelix.","Transaction expected to close before end of August 2025, subject to Antev shareholder approval and other conditions.","Antev's lead asset Teverelix targets two indications: acute urinary retention (Phase 2b) and high-CV-risk advanced prostate cancer (Phase 2b).","Consideration shares subject to 9-month staggered lock-up and 36-month voting agreement with Medicus management."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":163444,"accession_number":"0001062993-25-012044","cik":1997296,"company_name":"Medicus Pharma Ltd.","ticker":"MDCX","form_type":"8-K","filed_at":"2025-06-23T23:59:59+00:00","items":["5.02","8.01","9.01"],"status":"ready","headline":"Medicus Pharma appoints Andrew Smith COO; Phase 2 BCC trial randomized >50 of 90 patients","event_type":"other_material","confidence":"high","bullets":["Andrew Smith appointed COO effective June 30, 2025; base salary $325K, 100k stock options at $2.60 vesting quarterly over 5 years.","Phase 2 SKNJCT-003 for BCC using D-MNA has randomized >50 of 90 patients across 9 US sites; interim analysis showed >60% clinical clearance (preliminary).","Clinical expansion: European sites plus UAE study SKNJCT-004 (36 patients, 4 sites); Cleveland Clinic Abu Dhabi as PI.","Previously announced binding LOI to acquire Antev Ltd. for Teverelix GnRH antagonist; no new terms disclosed."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":163443,"accession_number":"0001062993-25-011991","cik":1997296,"company_name":"Medicus Pharma Ltd.","ticker":"MDCX","form_type":"8-K","filed_at":"2025-06-20T23:59:59+00:00","items":["1.01","2.03","9.01"],"status":"ready","headline":"Medicus Pharma issues third debenture for $2.5M, completing $5M Yorkville facility","event_type":"debt","confidence":"high","bullets":["On June 17, 2025, issued third debenture to YA II PN, Ltd. for $2.5M principal, net proceeds $2.25M.","Total aggregate principal from three debentures now $5M; net proceeds to Company $4.5M.","Debentures bear 8% annual interest (18% upon default), mature February 2, 2026, guaranteed by subsidiaries."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":163442,"accession_number":"0001062993-25-011051","cik":1997296,"company_name":"Medicus Pharma Ltd.","ticker":"MDCX","form_type":"8-K","filed_at":"2025-06-05T23:59:59+00:00","items":["4.01","9.01"],"status":"ready","headline":"Medicus Pharma dismisses EisnerAmper, engages KPMG as auditor","event_type":"other_material","confidence":"high","bullets":["Dismissed EisnerAmper on June 3, 2025; engaged KPMG on June 4, 2025.","EisnerAmper's 2024 audit report included a going-concern qualification.","Material weaknesses in internal controls identified; no restatement occurred.","No disagreements on accounting principles or practices with EisnerAmper.","KPMG appointed as independent auditor for the fiscal year ending Dec 31, 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.65,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":163441,"accession_number":"0001062993-25-010687","cik":1997296,"company_name":"Medicus Pharma Ltd.","ticker":"MDCX","form_type":"8-K","filed_at":"2025-06-02T23:59:59+00:00","items":["1.01","3.02","8.01","9.01"],"status":"ready","headline":"Medicus Pharma prices $7M public offering of 2.26M units at $3.10/unit; closes June 2","event_type":"other_material","confidence":"high","bullets":["Gross proceeds $7,006,000 from 2,260,000 units at $3.10/unit; each unit = 1 common share + 1 warrant.","Warrants exercisable at $3.10/share, expire 5 years from issuance; not listed on exchange.","Net proceeds to fund Phase 2 proof-of-concept trial for basal cell carcinoma using doxorubicin tip loaded dissolvable microarray needle skinpatch.","Co. also issued $1.25M second-tranche debenture to Yorkville on June 2, 2025, bringing total Yorkville debentures to $2.5M.","Placement agents Maxim, Brookline, D. Boral; cash fee 7.5% of gross proceeds."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}